StocksS › SSDOY

Shiseido Company, Limited (SSDOY) — Earnings Call X-Ray

Our AI read all 13 of SSDOY's earnings calls (2020–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q4 2024 · sign up to see
Previous Call Grade
F
Q3 2024
Expected Move
🔒
next 45 days · members
Calls Analyzed
13
2020–2025
Avg Candor
6.8/9
evasion 3.5/9
Guidance LoweredHigh CandorEvasive ManagementCritic AmmunitionEarly Product, Fast GrowthUnderused Fixed CostsRaising PricesMargins Contracting

Call-by-call analysis

🔒 Q4 2024 earnings call 2025-02-11 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q4 2024 call grade is ready
The full 37-point AI read of SSDOY's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

F Q3 2024 earnings call 2024-11-09 move ±11.1%

Management lowered guidance against slowing demand and contracting margins. The delivery was unusually candid, frequently evasive.

Guidance: loweredDemand: slowingMargins: contractingPricing: raisingHeadcount: cutting 7 analysts · 10 questions
⚑ Critic ammunition⚑ Question left hanging✓ Early product, fast growthHidden segmentCFO dominatesDirection beats results
Candor 7/9
Specificity 6/9
Evasion 6/9
Confidence 4/9
Uncertainty 6/9
Promotion 3/9
Stress 5/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

D Q2 2024 earnings call 2024-08-10 move ±10.6%

Management held guidance steady against slowing demand and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: slowingMargins: contractingPricing: under pressureHeadcount: cutting 7 analysts · 9 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedCFO dominates
Candor 7/9
Specificity 7/9
Evasion 3/9
Confidence 5/9
Uncertainty 6/9
Promotion 2/9
Stress 5/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q1 2024 earnings call 2024-05-10 move ±10.1%

Management held guidance steady against mixed demand signals and contracting margins. The delivery was rich in specifics.

Guidance: maintainedDemand: mixedMargins: contractingPricing: raisingHeadcount: cutting 6 analysts · 13 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 7/9
Uncertainty 5/9
Promotion 4/9
Stress 4/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q4 2023 earnings call 2024-02-09 move ±8.7%

Management held guidance steady against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: mixedMargins: contractingPricing: raisingHeadcount: cuttingCapex: flat 6 analysts · 13 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedHidden segmentDirection beats results
Candor 7/9
Specificity 7/9
Evasion 3/9
Confidence 5/9
Uncertainty 4/9
Promotion 3/9
Stress 4/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q3 2023 earnings call 2023-11-11 move ±13.3%

Management lowered guidance against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: loweredDemand: mixedMargins: contractingPricing: raisingHeadcount: cuttingCapex: decreasing 7 analysts · 12 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedHidden segmentCFO dominatesDirection beats results
Candor 7/9
Specificity 8/9
Evasion 3/9
Confidence 5/9
Uncertainty 6/9
Promotion 2/9
Stress 4/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q2 2023 earnings call 2023-08-12 move ±7.3%

Management held guidance steady against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: mixedMargins: expandingPricing: raisingHeadcount: cutting 6 analysts · 14 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts✓ Early product, fast growthHidden segmentCFO dominates
Candor 7/9
Specificity 7/9
Evasion 4/9
Confidence 7/9
Uncertainty 5/9
Promotion 3/9
Stress 4/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

C Q1 2023 earnings call 2023-05-12 move ±8.3%

Management held guidance steady against mixed demand signals and expanding margins. The delivery was rich in specifics.

Guidance: maintainedDemand: mixedMargins: expandingPricing: raisingHeadcount: cutting 9 analysts · 18 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth
Candor 6/9
Specificity 7/9
Evasion 3/9
Confidence 7/9
Uncertainty 5/9
Promotion 4/9
Stress 3/9
Complexity 6/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q4 2022 2023-02-11 C maintainedmixedexpanding 7/9 2/9
Q3 2022 2022-11-12 D maintainedmixedcontracting 6/9 4/9
Q2 2022 2022-08-10 F loweredmixedcontracting 7/9 3/9
Q4 2020 2021-02-09 C+ raisedmixedexpanding 7/9 4/9
Q2 2020 2020-08-09 F loweredmixedcontracting 8/9 4/9

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAMC · Altisource Asset ManagemAAON · AAON, Inc.AASZF · Atlantic Sapphire ASAAAT · American Assets Trust, IABCD · Cambium Learning Group'sABCO · The Advisory Board

SSDIY   All “S” companies    SSE

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.